Crinetics Pharmaceuticals Inc (CRNX)

In January 2026, Goldman Sachs upgraded CRNX to 'Buy', and Morgan Stanley raised its price target, while Citizens lowered its price target. Crinetics announced a public offering of common stock, and positive updates on PALSONIFY and atumelnant coincided with positive stock reactions. In December 2025, the first patient was dosed in the pivotal CALM-CAH Phase 3 trial for atumelnant, and the first patient was dosed in a Phase 1/2 trial for CRN09682. In November 2025, Crinetics reported Q3 earnings, missing analyst estimates, and Citizens lowered its price target. In September 2025, Oppenheimer raised its price target, and the FDA's PDUFA target action date for paltusotine's NDA for acromegaly was September 25, 2025. In August 2025, the company reported Q2 financial results, missing earnings and revenue estimates.

Specific demand seasonality for Crinetics Pharmaceuticals' products is not extensively documented. While stock analysis suggests seasonal strength from March 25 to June 23, this may not reliably indicate product demand seasonality. The Healthcare sector typically experiences seasonal strength from April 25 to December 4. Demand for Crinetics' products is likely driven by ongoing medical need and treatment cycles rather than typical consumer seasonal purchasing patterns.

Crinetics Pharmaceuticals, Inc. is focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's primary product is PALSONIFY (paltusotine), an oral agonist approved for adults with acromegaly and in clinical development for carcinoid syndrome. Atumelnant (CRN049894) is an investigational oral antagonist in clinical development for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. CRN09682 is a nonpeptide drug conjugate targeting SST2 positive solid tumors. The company also has programs for hyperparathyroidism, thyroid eye disease, Graves' disease, polycystic kidney disease, diabetes, obesity, and GPCR-targeted oncology indications, along with partnerships with Loyal and Radionetics Oncology.

Crinetics Pharmaceuticals is headquartered in San Diego, California, and expanded internationally by establishing an office in Zug, Switzerland, in 2024. The company is pursuing market expansion in Europe with regulatory reviews for Paltusotine and has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd for development and commercialization of Paltusotine in Japan.

Crinetics Pharmaceuticals' brand reputation has been positively influenced by the commercial launch of PALSONIFY in the U.S. and positive clinical trial data for atumelnant. The company's strong balance sheet and funding outlook also contribute positively. Challenges include weak current financial performance, missing analyst estimates, and a public offering of common stock that negatively impacted the stock price. Weiss Ratings reissued a "sell" rating in October 2025.

Crinetics Pharmaceuticals has significant institutional ownership, with 520 institutional owners holding over 123 million shares, representing between 76.82% and 98.51% of the company's stock. Major institutional holders include Fmr Llc, Vanguard Group Inc, Wellington Management Group Llp, and BlackRock, Inc. Insider ownership ranges from approximately 1.93% to 6.00%. Perceptive Advisors LLC is a notable individual shareholder, holding 7.91 million shares, representing 8.33% of the company. Insider selling has exceeded buying in the past three months.